Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric nilotinib pharmacokinetic study in Philadelphia chromosome-positive leukemia
NL-OMON39198Active, not recruiting
- Sponsor
- Novartis
- Start
- May 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of nilotinib in chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL), sponsored by Novartis. Primary endpoint: Pharmacokinetic parameters of nilotinib. Started May 2011; status: active, not recruiting.
02
Drugs
nilotinib
03
Conditions
chronic myelogenous leukemia (CML)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NL-OMON39198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39198.